Overview

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil